Commitment
Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic identifies the patients with the corresponding molecular signature who are the best candidates for therapy.
News & Events
Andarix Pharmaceuticals to Present Targeted Lung Cancer Technology at Clinical Conference
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 12, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a clinical provider conference. The conference will focus on…
Read MoreAndarix Pharmaceuticals to Present Lung Cancer Therapy Technology at Clinical Trials Conference
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —July 23, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a therapeutics conference. The conference will focus on a diversity…
Read MoreAndarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
Targeted therapy for cancer is based on personalized medicine approach SOMERVILLE, MA — March 2, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office. About Tozaride Tozaride is…
Read More